贝伐单抗（Bev）是一种靶向血管内皮生长因子A的人源化单克隆抗体，主要用于治疗各种实体瘤。主动脉夹层（AD）是由于主动脉内膜层撕裂或主动脉壁内出血，导致主动脉壁不同层分离而引起的严重血管疾病。然而，发病机制尚不完全清楚。有研究提示Bev治疗与AD的发生有关。 一名67岁的中国男性被诊断出患有直肠癌并伴有肝和肺转移。开始 Bev 联合化疗三天后，患者出现持续性腹痛。腹部CT扫描显示腹主动脉存在腹腔干AD，诊断为直肠癌并伴有肝、肺转移。腹部CT断层检查提示腹腔干AD，采用生长抑素联合缬沙坦控制血压。该患者随后被转诊进行血管手术并接受腹主动脉血管造影。继续保守治疗。开始治疗3个月后，随访腹部CT显示腹腔干AD病情稳定，无腹痛、高血压。没有任何夹层恶化、动脉瘤形成或终末器官灌注不足的迹象。Bev 与血压升高以及腹腔干 AD 之间可能存在联系。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

Bevacizumab (Bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor A and is primarily used for the treatment of various solid tumors. Aortic dissection (AD) is a severe vascular disease caused by the tearing of the intimal layer of the aorta or bleeding within the aortic wall, resulting in the separation of different layers of the aortic wall. However, the pathogenesis is not fully understood. Some studies have suggested that Bev treatment is associated with the occurrence of AD.A 67-year-old Chinese male was diagnosed with rectal cancer accompanied by liver and lung metastasis. Three days after starting combined chemotherapy with Bev, the patient developed persistent abdominal pain. Abdominal CT scan revealed celiac trunk AD in the abdominal aorta.The patient was diagnosed with rectal cancer accompanied by liver and lung metastases. Abdominal CT tomography revealed a celiac trunk AD.Somatostatin combined with valsartan was used to control blood pressure. The patient was subsequently referred for vascular surgery and underwent an abdominal aortic angiography. Conservative treatment was continued.Three months after the initiation of treatment, follow-up abdominal CT scans showed stability in the condition of celiac trunk AD, with no abdominal pain or hypertension. There were no signs of worsening dissection, aneurysm formation, or inadequate perfusion of end organs.There may be a connection between Bev and elevated blood pressure as well as celiac trunk AD.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.